Diabetes, Glycemic Control and Risk of Medical Glaucoma Treatment: A Population-based Case-control Study

Overview

Journal Clin Epidemiol

Publisher Dove Medical Press

Specialty Public Health

Date 2010 Sep 25

PMID 20865094

Citations 7

Authors

Lotte G Welinder

Anders H Riis

Lars L Knudsen

Reimar W Thomsen

Affiliations

Soon will be listed here.

Abstract

Purpose: To examine the association between diabetes and risk of medical glaucoma treatment and to assess the role of long-term glycemic control in the putative association.

Design: Population-based case-control study.

Methods: Cases of treated glaucoma were all persons filling at least three prescriptions for glaucoma medication for the first time within one year between 2001 and 2006 in Northern Jutland, Denmark. We used risk set sampling to select 10 gender- and age-matched general population controls per case using the Danish Civil Registration System. Data on diabetes, comorbidities, and laboratory tests, including glycosylated hemoglobin (as a measure of glycemic control) were obtained from population-based medical registries. We calculated odds ratio (OR) as an estimate of relative risk for treated glaucoma comparing patients with and without diabetes, adjusted for comorbid conditions and medication use.

Results: We included 5,991 persons with incident medical glaucoma treatment and 59,910 population controls. The adjusted OR for treated glaucoma for patients with diabetes was 1.81 (95% confidence interval: 1.65-1.98). The strength of the association between diabetes and glaucoma risk did not vary by diabetes duration or by the level of glycemic control.

Conclusions: Regardless of glycemic control, diabetes is associated with a substantially increased risk for medical glaucoma treatment.

Citing Articles

Possible Causal Association between Type 2 Diabetes and Glycaemic Traits in Primary Open-Angle Glaucoma: A Two-Sample Mendelian Randomisation Study.

Seo J, Lee Y Biomedicines. 2024; 12(4).

PMID: 38672220 PMC: 11048047. DOI: 10.3390/biomedicines12040866.

Presence and severity of migraine is associated with development of primary open angle glaucoma: A population-based longitudinal cohort study.

Ohn K, Han K, Moon J, Jung Y PLoS One. 2023; 18(3):e0283495.

PMID: 36961849 PMC: 10038297. DOI: 10.1371/journal.pone.0283495.

Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?.

Mouhammad Z, Vohra R, Horwitz A, Thein A, Rovelt J, Cvenkel B Front Neurosci. 2022; 16:824054.

PMID: 35264926 PMC: 8899005. DOI: 10.3389/fnins.2022.824054.

Migraine as a risk factor for primary open angle glaucoma: A systematic review and meta-analysis.

Xu C, Li J, Li Z, Mao X Medicine (Baltimore). 2018; 97(28):e11377.

PMID: 29995778 PMC: 6076184. DOI: 10.1097/MD.0000000000011377.

Lack of Correlation Between Diabetic Macular Edema and Thickness of the Peripapillary Retinal Nerve Fibre Layer.

Alkuraya H, Al-Gehedan S, Alsharif A, Alasbali T, Lotfy N, Khandekar R Middle East Afr J Ophthalmol. 2016; 23(3):241-6.

PMID: 27555707 PMC: 4968144. DOI: 10.4103/0974-9233.186097.

References

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

Thomsen R, Hundborg H, Lervang H, Johnsen S, Schonheyder H, Sorensen H . Risk of community-acquired pneumococcal bacteremia in patients with diabetes: a population-based case-control study. Diabetes Care. 2004; 27(5):1143-7. DOI: 10.2337/diacare.27.5.1143. View

Ellis J, Morris A, MacEwen C . Should diabetic patients be screened for glaucoma? DARTS/MEMO Collaboration. Br J Ophthalmol. 1999; 83(3):369-72. PMC: 1722975. DOI: 10.1136/bjo.83.3.369. View

Klein B, Klein R, Jensen S . Open-angle glaucoma and older-onset diabetes. The Beaver Dam Eye Study. Ophthalmology. 1994; 101(7):1173-7. DOI: 10.1016/s0161-6420(94)31191-2. View

Vestergaard P, Olsen M, Paaske Johnsen S, Rejnmark L, Sorensen H, Mosekilde L . Corticosteroid use and risk of hip fracture: a population-based case-control study in Denmark. J Intern Med. 2003; 254(5):486-93. DOI: 10.1046/j.1365-2796.2003.01219.x. View

Thomsen R, Hundborg H, Lervang H, Johnsen S, Sorensen H, Schonheyder H . Diabetes and outcome of community-acquired pneumococcal bacteremia: a 10-year population-based cohort study. Diabetes Care. 2003; 27(1):70-6. DOI: 10.2337/diacare.27.1.70. View

Leske M, Wu S, Hennis A, Honkanen R, Nemesure B . Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. Ophthalmology. 2007; 115(1):85-93. DOI: 10.1016/j.ophtha.2007.03.017. View

Barber A . A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27(2):283-90. DOI: 10.1016/S0278-5846(03)00023-X. View

Johnsen S, Pedersen L, Friis S, Blot W, McLaughlin J, Olsen J . Nonaspirin nonsteroidal anti-inflammatory drugs and risk of hospitalization for intracerebral hemorrhage: a population-based case-control study. Stroke. 2003; 34(2):387-91. DOI: 10.1161/01.str.0000054057.11892.5b. View

10.

Quigley H, Friedman D, Hahn S . Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study. Ophthalmology. 2007; 114(9):1599-606. DOI: 10.1016/j.ophtha.2007.03.042. View

11.

Su D, Wong T, Wong W, Saw S, Tan D, Shen S . Diabetes, hyperglycemia, and central corneal thickness: the Singapore Malay Eye Study. Ophthalmology. 2007; 115(6):964-968.e1. DOI: 10.1016/j.ophtha.2007.08.021. View

12.

Tielsch J, Katz J, Quigley H, Javitt J, Sommer A . Diabetes, intraocular pressure, and primary open-angle glaucoma in the Baltimore Eye Survey. Ophthalmology. 1995; 102(1):48-53. DOI: 10.1016/s0161-6420(95)31055-x. View

13.

Bonovas S, Peponis V, Filioussi K . Diabetes mellitus as a risk factor for primary open-angle glaucoma: a meta-analysis. Diabet Med. 2004; 21(6):609-14. DOI: 10.1111/j.1464-5491.2004.01173.x. View

14.

Suzuki R, Hanada M, Fujii H, Kurimoto S . Effects of orally administered beta-adrenergic blockers and calcium-channel blockers on the intraocular pressure of patients with treated hypertension. Ann Ophthalmol. 1992; 24(6):220-3. View

15.

Andersen T, Madsen M, Jorgensen J, Mellemkjoer L, Olsen J . The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999; 46(3):263-8. View

16.

Hirooka K, Baba T, Fujimura T, Shiraga F . Prevention of visual field defect progression with angiotensin-converting enzyme inhibitor in eyes with normal-tension glaucoma. Am J Ophthalmol. 2006; 142(3):523-5. DOI: 10.1016/j.ajo.2006.04.020. View

17.

Shah G, Sharma S, Mehta A, Goyal R . Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma. J Cardiovasc Pharmacol. 2000; 36(2):169-75. DOI: 10.1097/00005344-200008000-00005. View

18.

Mitchell P, Smith W, Chey T, Healey P . Open-angle glaucoma and diabetes: the Blue Mountains eye study, Australia. Ophthalmology. 1997; 104(4):712-8. DOI: 10.1016/s0161-6420(97)30247-4. View

19.

Mahmood K, Aamir A . Glycemic control status in patients with type-2 diabetes. J Coll Physicians Surg Pak. 2005; 15(6):323-5. DOI: 06.2005/JCPSP.323325. View

20.

Quigley H . Can diabetes be good for glaucoma? Why can't we believe our own eyes (or data)?. Arch Ophthalmol. 2009; 127(2):227-9. DOI: 10.1001/archophthalmol.2008.596. View